title: A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus.
abstract: In the search for an optimal approach for the transcutaneous immunization (TCI) of hepatitis B surface antigen (HBsAg), two vesicle formulations, L595 vesicles (composed of sucrose-laurate ester and octaoxyethylene-laurate ester) and sPC vesicles (composed of soybean-phosphatidylcholine and Span-80) were prepared and characterized in vitro and in vivo. HBsAg was associated to the vesicles, resulting in sPC-HBsAg vesicles (±170nm) with 79% HBsAg association and L595-HBsAg vesicles (±75nm) with only 29% HBsAg association. The vesicles induced in mice via TCI an antibody response only when the skin was pretreated with microneedles. This response was improved by the adjuvant cholera toxin. The sPC-HBsAg vesicle formulations showed to be the most immunogenic for TCI, which was related to the higher degree of HBsAg association.
authors.affiliation: Unit Vaccinology, National Institute for Public Health and the Environment (RIVM), A. van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
authors.forename: Hoang
authors.initials: H
authors.lastname: Hirschberg
authors.forename: Sandra
authors.initials: S
authors.lastname: van Kuijk
authors.forename: Jessica
authors.initials: J
authors.lastname: Loch
authors.forename: Wim
authors.initials: W
authors.lastname: Jiskoot
authors.forename: Joke
authors.initials: J
authors.lastname: Bouwstra
authors.forename: Gideon
authors.initials: G
authors.lastname: Kersten
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Amorij
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000279:Administration, Cutaneous; D000818:Animals; D002772:Cholera Toxin / Q000008:administration & dosage; D002850:Chromatography, Gel; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage* / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006601:Hexoses / Q000737:chemistry; D007074:Immunoglobulin G / Q000097:blood; D007848:Laurates / Q000737:chemistry; D008081:Liposomes / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D010316:Particle Size; D010713:Phosphatidylcholines / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D012867:Skin / Q000378:metabolism; D013395:Sucrose / Q000737:chemistry; D014611:Vaccination / Q000379:methods*
chemical_list: D000276:Adjuvants, Immunologic; D006514:Hepatitis B Surface Antigens; D006601:Hexoses; D007074:Immunoglobulin G; D007848:Laurates; D008081:Liposomes; D010713:Phosphatidylcholines; C561032:octaoxyethylene-laurate ester; C018665:sorbitan monooleate; D011092:Polyethylene Glycols; D013395:Sucrose; D002772:Cholera Toxin